You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Harvard Business School
Boehringer Ingelheim
Moodys
Mallinckrodt

Last Updated: March 31, 2020

DrugPatentWatch Database Preview

DEFERASIROX Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which patents cover Deferasirox, and what generic alternatives are available?

Deferasirox is a drug marketed by Actavis Elizabeth, Alembic Pharms Ltd, Alkem Labs Ltd, Bionpharma Inc, Ichnos, MSN, Sun Pharm, Amneal Pharms Co, Piramal Hlthcare Uk, Teva Pharms Usa, and Zydus Pharms. and is included in fifteen NDAs.

The generic ingredient in DEFERASIROX is deferasirox. There are twenty drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the deferasirox profile page.

US ANDA Litigation and Generic Entry Outlook for Deferasirox

A generic version of DEFERASIROX was approved as deferasirox by ACTAVIS ELIZABETH on January 26th, 2016.

  Start Trial

Drug patent expirations by year for DEFERASIROX
Drug Prices for DEFERASIROX

See drug prices for DEFERASIROX

Recent Clinical Trials for DEFERASIROX

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Fondazione Italiana Sindromi Mielodisplastiche OnlusPhase 2
DisperSol Technologies, LLCPhase 2
Fred Hutchinson Cancer Research CenterPhase 2

See all DEFERASIROX clinical trials

Recent Litigation for DEFERASIROX

Identify potential future generic entrants

District Court Litigation
Case NameDate
ALEMBIC PHARMACEUTICALS, LTD v. NOVARTIS PHARMACEUTICALS CORP.2019-11-27
Novartis Pharmaceuticals Corporation v. Teva Pharmaceuticals USA, Inc.2016-07-29
Novartis Pharmaceuticals Corporation v. Mylan Inc.2014-06-26

See all DEFERASIROX litigation

Synonyms for DEFERASIROX
1044764-54-6
201530-41-8
4-((3E,5E)-3,5-bis(6-oxocyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl)benzoic acid
4-((3Z,5E)-3,5-bis(6-oxocyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl)benzoic acid
4-(3,5-Bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)benzoic acid
4-[(3Z,5E)-3,5-Bis(6-Oxo-2,4-cyclohexadien-1-ylidene)-1,2,4-triazolidin-1-yl]benzoic acid, AldrichCPR
4-[(3Z,5E)-3,5-bis(6-oxocyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl]benzoic acid
4-[3,5-bis(2-hydroxyphenyl)
4-[3,5-Bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid
4-[3,5-Bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid
4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid
4-[3,5-bis(6-oxidanylidenecyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl]benzoic acid
4-[3,5-bis(6-oxo-1-cyclohexa-2,4-dienylidene)-1,2,4-triazolidin-1-yl]benzoic acid
530D418
A814288
AB0020007
AB0073018
AB01565800_02
AB1008603
AC-8972
ACM1133425758
AK544293
AKOS015855839
AKOS015902587
AKOS025312553
BCP05341
BCP9000594
BDBM50088376
Benzoic acid, 4-(3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)-
Benzoic acid, 4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]-
BOFQWVMAQOTZIW-UHFFFAOYSA-N
C21H15N3O4
CAS-201530-41-8
CGP-72670
CHEBI:49005
CHEMBL550348
CS-0901
CTK8F0690
D03669
DB01609
Deferasirox (Exjade)
Deferasirox (JAN/USAN/INN)
Deferasirox [USAN:INN:JAN]
Deferasirox [USAN:INN]
Deferasirox, ICL670
Deferasirox(Exjade)
Deferasiroxum
Deferasiroxum [INN-Latin]
DSSTox_CID_28522
DSSTox_GSID_48596
DSSTox_RID_82794
DTXSID1048596
Exjade
Exjade (TN)
F0001-2380
FT-0601564
HMS3655A04
HSDB 7844
HY-17359
ICL 670
ICL 670A
ICL-670
ICL-670A
ICL670
ICL670A
J-013060
Jadenu
Jadenu (TN)
Jadenu Sprinkle
KE-0220
KS-00000G02
LS-186571
LS-187785
MLS003915634
MLS006010080
NCGC00181754-01
NCGC00263572-01
PubChem20503
Q5251502
s1712
SB18926
SCHEMBL1071867
SCHEMBL61756
SCHEMBL62042
SMR002544689
SR-01000931971
SR-01000931971-2
SW219752-1
Tox21_112926
Tox21_112926_1
UNII-V8G4MOF2V9
V0697
V8G4MOF2V9
W-5422
ZINC100022643
ZINC100504305
ZINC100504309
ZINC1481815
ZINC14880008
Paragraph IV (Patent) Challenges for DEFERASIROX
Tradename Dosage Ingredient NDA Submissiondate
JADENU TABLET;ORAL deferasirox 206910 2016-04-21
JADENU TABLET;ORAL deferasirox 206910 2015-10-19
EXJADE TABLET, FOR SUSPENSION;ORAL deferasirox 021882 2011-10-28

US Patents and Regulatory Information for DEFERASIROX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Piramal Hlthcare Uk DEFERASIROX deferasirox TABLET;ORAL 212995-002 Dec 30, 2019 AB RX No No   Start Trial   Start Trial   Start Trial
Amneal Pharms Co DEFERASIROX deferasirox TABLET;ORAL 210727-002 Dec 27, 2019 AB RX No No   Start Trial   Start Trial   Start Trial
Sun Pharm DEFERASIROX deferasirox TABLET;ORAL 211641-001 Jan 2, 2020 AB RX No No   Start Trial   Start Trial   Start Trial
Msn DEFERASIROX deferasirox TABLET;ORAL 210945-001 Nov 20, 2019 AB RX No No   Start Trial   Start Trial   Start Trial
Actavis Elizabeth DEFERASIROX deferasirox TABLET, FOR SUSPENSION;ORAL 203560-001 Jan 26, 2016 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Harvard Business School
Boehringer Ingelheim
Moodys
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.